Sun Pharma places non-binding offer for US-based Organon in its boldest global bet ever
The Economic Times·2026-01-20 08:00
Sun has already tied up acquisition financing in the form of bridge loans from at least three global banks — one each from Wall Street, Europe and Japan — to the tune of $10-14 billion to show its commitment to the board of Organon.The due diligence process will start shortly, following which a binding bid will be made. But being a listed company, typically these dilligences are much shorter in nature. ET was the first to report January 19 on Sun making a play for Organon. The company told the exchanges th ...